← Back to Tru in the News
MC
Manufacturing Chemist
October 2026

ARPA-H SURPASS Programme Targets Phaseless Clinical Trials

Manufacturing Chemist covers ARPA-H's SURPASS programme and its focus on phaseless clinical trials. The article looks at what moving beyond traditional trial phases could mean for how new therapies are developed and tested.

Read the full article on Manufacturing Chemist

More from Tru in the News

CTA
Clinical Trials Arena

OCT SoCal 2026: Sound governance and collaboration lead the way as regulation percolates

October 2026
BI
BioProcess International

FDA Rolls Out Expedited Pilot Program to Address Bottlenecks in Clinical Trials

October 2026
ACT
Applied Clinical Trials

HHS Launches SURPASS Program and Three Complementary Initiatives to Transform Clinical Trial Design and Infrastructure

October 2026